Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


June 29, 2015 11:37 PM ET

Biotechnology

Company Overview of Perosphere Inc.

Company Overview

Perosphere Inc., a specialty pharmaceutical company, provides drug delivery technology. Its drug delivery technology enables localized and systemic delivery, alters pharmacokinetics and pharmacodynamics to improve controlled release formulations, and reduces inter and intra-patient variability. The company’s drug delivery technology is used in drug candidates, such as PER726, an intravenous therapeutic drug; PER921 and PER922, which are oral solid dose therapeutic drugs; PER923, a low dose administration of a therapeutic drug; PER1080, a rapid-acting formulation of a therapeutic drug; and PER977 to reverse the anticoagulant activity of unfractionated heparin, low molecular weight heparins, f...

24 Old Wagon Road

Bedford, NY 10549

United States

Founded in 2011

Key Executives for Perosphere Inc.

Founder, Chairman, Chief Executive Officer and President
Age: 76
Founder, Chief Technology Officer and Vice President
Founder and Vice President of Research
Founder and Chief Scientific Officer
Chief Financial Officer, Vice President of Finance and Treasurer
Compensation as of Fiscal Year 2014.

Perosphere Inc. Key Developments

Perosphere Inc. Receives FDA Fast Track Designation for Investigational Anticoagulant Reversal Agent PER977

Perosphere Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for PER977, an investigational anticoagulant reversal agent. The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. An important feature of Fast Track is that the FDA may grant frequent and expedited interactions to discuss study design, extent of safety data required to support approval, dose-response concerns, and use of biomarkers. Fast Track also offers the opportunity for the FDA to consider a "rolling review" of completed sections of the New Drug Application (NDA) before the complete application is submitted.

Perosphere Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015

Perosphere Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Perosphere Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Perosphere Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
Periphagen Holdings, Inc. United States
Nuvera Biosciences, Inc. United States
Algal Scientific Corporation United States
X-Ceptor Therapeutics, Inc. United States
Lifecode, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Perosphere Inc., please visit www.perosphere.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.